Alan K. Burnett,on behalf of the UK National Cancer Research Institute AML Working Group,Nigel H. Russell,on behalf of the UK National Cancer Research Institute AML Working Group,Ann E. Hunter,on behalf of the UK National Cancer Research Institute AML Working Group,Donald Milligan,on behalf of the UK National Cancer Research Institute AML Working Group,Steven Knapper,on behalf of the UK National Cancer Research Institute AML Working Group,Keith Wheatley,on behalf of the UK National Cancer Research Institute AML Working Group,John Yin,on behalf of the UK National Cancer Research Institute AML Working Group,Mary F. McMullin,on behalf of the UK National Cancer Research Institute AML Working Group,Sahra Ali,on behalf of the UK National Cancer Research Institute AML Working Group,David Bowen,on behalf of the UK National Cancer Research Institute AML Working Group,Robert K. Hills,on behalf of the UK National Cancer Research Institute AML Working Group

View Articletitled, Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Brief Report

Ayalew Tefferi,Francisco Cervantes,Ruben Mesa,Francesco Passamonti,Srdan Verstovsek,Alessandro M. Vannucchi,Jason Gotlib,Brigitte Dupriez,Animesh Pardanani,Claire Harrison,Ronald Hoffman,Heinz Gisslinger,Nicolaus Kröger,Juergen Thiele,Tiziano Barbui,Giovanni Barosi

View Articletitled, Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

Supplemental data

GENE THERAPY

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

Daniel Abate-Daga,Ken-ichi Hanada,Jeremy L. Davis,James C. Yang,Steven A. Rosenberg,Richard A. Morgan

View Articletitled, Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

Supplemental data

IMMUNOBIOLOGY

Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage

André Cohnen,Samuel C. Chiang,Ana Stojanovic,Hendrik Schmidt,Maren Claus,Paul Saftig,Ottmar Janßen,Adelheid Cerwenka,Yenan T. Bryceson,Carsten Watzl

View Articletitled, Surface CD107a/LAMP-1 protects natural killer cells from degranulation-associated damage

Supplemental data

Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2–dependent prostaglandin E2 in human dendritic cells

Jamma Trinath,Pushpa Hegde,Meenu Sharma,Mohan S. Maddur,Magalie Rabin,Jean-Michel Vallat,Laurent Magy,Kithiganahalli N. Balaji,Srini V. Kaveri,Jagadeesh Bayry

View Articletitled, Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2–dependent prostaglandin E2 in human dendritic cells

The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo

Vicky Louise Morrison,Matthew MacPherson,Terhi Savinko,Hwee San Lek,Alan Prescott,Susanna Carola Fagerholm

View Articletitled, The β2 integrin–kindlin-3 interaction is essential for T-cell homing but dispensable for T-cell activation in vivo

An evolutionarily conserved program of B-cell development and activation in zebrafish
e-blood

Dawne M. Page,Valerie Wittamer,Julien Y. Bertrand,Kanako L. Lewis,David N. Pratt,Noemi Delgado,Sarah E. Schale,Caitlyn McGue,Bradley H. Jacobsen,Alyssa Doty,Yvonne Pao,Hongbo Yang,Neil C. Chi,Brad G. Magor,David Traver

View Articletitled, An evolutionarily conserved program of B-cell development and activation in zebrafish

Supplemental data

LYMPHOID NEOPLASIA

RARα2 expression confers myeloma stem cell features

Ye Yang,Jumei Shi,Giulia Tolomelli,Hongwei Xu,Jiliang Xia,He Wang,Wen Zhou,Yi Zhou,Satyabrata Das,Zhimin Gu,Dana Levasseur,Fenghuang Zhan,Guido Tricot

View Articletitled, RARα2 expression confers myeloma stem cell features

Supplemental data

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Miguel Alcoceba,Elena Sebastián,Luis Marín,Ana Balanzategui,M. Eugenia Sarasquete,M. Carmen Chillón,Cristina Jiménez,Noemí Puig,Rocío Corral,Emilia Pardal,Carlos Grande,José Luis Bello,Carmen Albo,Fátima de la Cruz,Carlos Panizo,Alejandro Martín,Eva González-Barca,M. Dolores Caballero,Jesús F. San Miguel,Ramón García-Sanz,Marcos González

View Articletitled, HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

Supplemental data

MYELOID NEOPLASIA

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S. Kung Sutherland,Roland B. Walter,Scott C. Jeffrey,Patrick J. Burke,Changpu Yu,Heather Kostner,Ivan Stone,Maureen C. Ryan,Django Sussman,Robert P. Lyon,Weiping Zeng,Kimberly H. Harrington,Kerry Klussman,Lori Westendorf,David Meyer,Irwin D. Bernstein,Peter D. Senter,Dennis R. Benjamin,Jonathan G. Drachman,Julie A. McEarchern

View Articletitled, SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

Supplemental data

JAK2^V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα

Salma Hasan,Catherine Lacout,Caroline Marty,Marie Cuingnet,Eric Solary,William Vainchenker,Jean-Luc Villeval

View Articletitled, JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα

Supplemental data

THROMBOSIS AND HEMOSTASIS

Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels

Somadri Ghosh,Dhananjay Shukla,Komjeti Suman,B. Jyothi Lakshmi,R. Manorama,Satish Kumar,Rashna Bhandari

View Articletitled, Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels

Supplemental data

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Shuju Feng,Stephen J. Eyler,Yuzhou Zhang,Tara Maga,Carla M. Nester,Michael H. Kroll,Richard J. Smith,Vahid Afshar-Kharghan

View Articletitled, Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Supplemental data

TRANSFUSION MEDICINE

Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model

Sean R. Stowell,Kate L. Henry,Nicole H. Smith,Krystalyn E. Hudson,Greg R. Halverson,Jaekeun C. Park,Ashley M. Bennett,Kathryn R. Girard-Pierce,C. Maridith Arthur,Silvia T. Bunting,James C. Zimring,Jeanne E. Hendrickson

View Articletitled, Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model

TRANSPLANTATION

Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality

John E. Levine,Elisabeth Huber,Suntrea T. G. Hammer,Andrew C. Harris,Joel K. Greenson,Thomas M. Braun,James L. M. Ferrara,Ernst Holler

View Articletitled, Low Paneth cell numbers at onset of gastrointestinal graft-versus-host disease identify patients at high risk for nonrelapse mortality

Supplemental data

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Corey Cutler,Haesook T. Kim,Bhavjot Bindra,Stefanie Sarantopoulos,Vincent T. Ho,Yi-Bin Chen,Jacalyn Rosenblatt,Sean McDonough,Phandee Watanaboonyongcharoen,Philippe Armand,John Koreth,Brett Glotzbecker,Edwin Alyea,Bruce R. Blazar,Robert J. Soiffer,Jerome Ritz,Joseph H. Antin

View Articletitled, Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses
Brief Report

Can M. Sungur,Yajarayma J. Tang-Feldman,Anthony E. Zamora,Maite Alvarez,Claire Pomeroy,William J. Murphy

View Articletitled, Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses

Supplemental data

VASCULAR BIOLOGY

Prolylcarboxypeptidase promotes angiogenesis and vascular repair

Gregory N. Adams,Evi X. Stavrou,Chao Fang,Alona Merkulova,M. Amer Alaiti,Kohsuke Nakajima,Toshifumi Morooka,Sergei Merkulov,Gretchen A. LaRusch,Daniel I Simon,Mukesh K. Jain,Alvin H. Schmaier

View Articletitled, Prolylcarboxypeptidase promotes angiogenesis and vascular repair

Supplemental data

ERRATA

Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120(18):3837-3845.

View Articletitled, Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012;120(18):3837-3845.

Cover Image

Cover Image

Immunofluorescence staining of developing microvasculature in a Matrigel plug in the flank of a wild-type mouse. The red-orange material is CD31; the green stain is NG2, a chondroitin 4 epitope that is a marker for vascular smooth muscle cells; and the yellow color is their colocalization. The balanced NG2/CD31 antigen ratio seen in this photomicrograph is contrasted with that seen in Matrigel plugs in PRCPgt/gt mice. Prolylcarboxypeptidase (PRCP) deficient cells have reduced endothelial cell growth and migration. PRCP deficient mice (PRCPgt/gt) have reduced angiogenesis and reduced the ability for ischemic repair. See the article by Adams et al on page 1522.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Targeting DOT1L and EZH2 synergizes in breaking the germinal center identity of Diffuse Large B-cell Lymphoma

High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell cytotoxicity in chronic myeloid leukemia

Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Doubling down on GPRC5D in multiple myeloma

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD

Transplants for the elderly in myeloma Clinical Trials & Observations

BLOOD WORK

PLENARY PAPER

REVIEW ARTICLE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results Clinical Trials & Observations

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival Clinical Trials & Observations

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report Brief Report

GENE THERAPY

IMMUNOBIOLOGY

An evolutionarily conserved program of B-cell development and activation in zebrafish e-blood

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

TRANSPLANTATION

Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses Brief Report

VASCULAR BIOLOGY

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Transplants for the elderly in myeloma
Clinical Trials & Observations

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results
Clinical Trials & Observations

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Clinical Trials & Observations

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Brief Report

An evolutionarily conserved program of B-cell development and activation in zebrafish
e-blood

Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses
Brief Report